Scleroderma - New aspects in pathogenesis and treatment

Best Practice and Research: Clinical Rheumatology

Volumn 26, Issue 1, 2012, Pages 13-24

  Balbir Gurman, Alexandra ^a   Braun Moscovici, Yolanda ^a  

^a B Shine Rheumatology Unit   (Israel)

Author keywords

Pathogenesis; Systemic sclerosis; Treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; AZATHIOPRINE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; IMMUNOGLOBULIN; METHOTREXATE; NITRATE; PHOSPHODIESTERASE INHIBITOR; PROSTANOID; PROTON PUMP INHIBITOR;

ADAPTIVE IMMUNITY; ARTHRITIS; ARTICLE; BACTERIAL INFECTION; BACTERIAL OVERGROWTH; CELLULAR IMMUNITY; GASTROESOPHAGEAL REFLUX; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INNATE IMMUNITY; INTESTINE INFECTION; LUNG ALVEOLITIS; LUNG FIBROSIS; MYOSITIS; PATHOGENESIS; PERICARDITIS; PLEURISY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS; ULCER; ULCER HEALING;

EID: 84858377734     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2012.01.011     Document Type: Review

References (90)

1. Y. Arnson, H. Amital, S. Guiducci, M. Matucci-Cerinic, G. Valentini, and O. Barzilai The role of infections in the immunopathogensis of systemic sclerosis-evidence from serological studies Annals of the New York Academy of Sciences 1173 2009 627 632
2. C. Grossman, Z. Dovrish, Y. Shoenfeld, and H. Amital Do infections facilitate the emergence of systemic sclerosis? Autoimmunity Reviews 10 2011 244 247
3. Y. Arnson, H. Amital, N. Agmon-Levin, D. Alon, M. Sánchez- Castañón, and M. López-Hoyos Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature Autoimmunity Reviews 10 2011 490 494
4. Y. Braun-Moscovici, D.E. Furst, D. Markovits, A. Rozin, P.J. Clements, and A.M. Nahir Vitamin D, parathyroid hormone, and acroosteolysis in systemic sclerosis Journal of Rheumatology 35 2008 2201 2205
5. A. Vacca, C. Cormier, M. Piras, A. Mathieu, A. Kahan, and Y. Allanore Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis Journal of Rheumatology 36 2009 1924 1929
6. R.K. Arora-Singh, S. Assassi, D.J. del Junco, F.C. Arnett, M. Perry, and U. Irfan Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis Journal of Autoimmunity 35 2010 52 57
7. Y. Allanore, P. Dieude, and C. Boileau Genetic background of systemic sclerosis: autoimmune genes take centre stage Rheumatology (Oxford) 49 2010 203 210
8. Z. Szekanecz, and A.E. Koch Endothelial cells in inflammation and angiogenesis Current Drug Targets 4 2005 319 323 (Pubitemid 40873118)
9. A. Pignone, C. Scaletti, M. Matucci-Cerinic, D. Vázquez-Abad, P.L. Meroni, and N. Del Papa Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment Clinical and Experimental Rheumatology 16 1998 527 532 (Pubitemid 28439433)
10. N. Del Papa, N. Quirici, C. Scavullo, U. Gianelli, L. Corti, and C. Vitali Antiendothelial cell antibodies induce apoptosis of bone marrow endothelial progenitors in systemic sclerosis Journal of Rheumatology 37 2010 2053 2063
11. M. Cutolo, A. Sulli, and V. Smith Assessing microvascular changes in systemic sclerosis diagnosis and management Nature Reviews Rheumatology 6 2010 578 587
12. H.M. Hofstee, A. Vonk Noordegraaf, A.E. Voskuyl, B.A. Dijkmans, P.E. Postmus, and Y.M. Smulders Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis Annals of the Rheumatic Diseases 68 2009 191 195
13. Y. Nagai, M. Yamanaka, C. Hashimoto, A. Nakano, A. Hasegawa, and Y. Tanaka Autopsy case of systemic sclerosis with severe pulmonary hypertension Journal of Dermatology 34 2007 769 772 (Pubitemid 350029297)
14. M. Manetti, S. Guiducci, E. Romano, C. Ceccarelli, S. Bellando-Randone, and M.L. Conforti Over-expression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis Circulation Research 109 2011 e14 e26
15. J.H. Distler, C. Beyer, G. Schett, T.F. Lüscher, S. Gay, and O. Distler Endothelial progenitor cells: novel players in the pathogenesis of rheumatic diseases Arthritis and Rheumatism 60 2009 3168 3179
16. V.S. Rajkumar, C. Sundberg, D.J. Abraham, K. Rubin, and C.M. Black Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis Arthritis and Rheumatism 42 1999 930 941 (Pubitemid 29215003)
17. D.J. Abraham, R. Vancheeswaran, M.R. Dashwood, V.S. Rajkumar, P. Pantelides, and S.W. Xu Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease American Journal of Pathology 151 1997 831 841 (Pubitemid 27385615)
18. M.H. Rustin, H.A. Bull, S.J. Machin, O. Koro, and P.M. Dowd Serum from patients with Raynaud's phenomenon inhibits prostacyclin production Journal of Investigative Dermatology 89 1987 555 559 (Pubitemid 18005491)
19. M. Manetti, A.F. Milia, S. Guiducci, E. Romano, M. Matucci-Cerinic, and L. Ibba-Manneschi Progressive loss of lymphatic vessels in skin of patients with systemic sclerosis Journal of Rheumatology 38 2011 297 301
20. J.C. Broen, L. Bossini-Castillo, L. van Bon, M.C. Vonk, H. Knaapen, and L. Beretta A rare polymorphism in Toll Like Receptor 2 is associated with systemic sclerosis phenotype and increases production of inflammatory mediators Arthritis and Rheumatism 2011 Sep 8 [Epub ahead of print]
21. D. Kim, A. Peck, D. Santer, P. Patole, S.M. Schwartz, and J.A. Molitor Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher INF-α activity with lung fibrosis Arthritis and Rheumatism 58 2008 2163 2173 (Pubitemid 351988110)
22. U.A. Walker, A. Tyndall, L. Czirják, C. Denton, D. Farge-Bancel, and O. Kowal-Bielecka Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database Annals of the Rheumatic Diseases 66 2007 754 763 (Pubitemid 46846694)
23. M. Koenig, F. Joyal, M.J. Fritzler, A. Roussin, M. Abrahamowicz, and G. Boire Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis Arthritis and Rheumatism 58 2008 3902 3912
24. A. Yoshizaki, K. Yanaba, A. Ogawa, Y. Asano, T. Kadono, and S. Sato Immunization with DNA topoisomerase I and complete Freund's adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling Arthritis and Rheumatism 2011 Jul 25 [Epub ahead of print]
25. Y. Hamaguchi, M. Fujimoto, M. Hasegawa, T. Matsushita, and K. Takehara Re-emergence of anti-topoisomerase I antibody with exacerbated development of skin sclerosis in a patient with systemic sclerosis Journal of the American Academy of Dermatology 62 2010 142 144
26. J.D. Reveille, D.H. Solomon, and American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies Arthritis and Rheumatism 49 2003 399 412 (Pubitemid 36682409)
27. T. Satoh, O. Ishikawa, H. Ihn, H. Endo, Y. Kawaguchi, and T. Sasaki Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay Rheumatology (Oxford) 48 2009 1570 1574
28. O. Meyer, L. De Chaisemartin, P. Nicaise-Roland, J. Cabane, F. Tubach, and P. Dieude Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study Journal of Rheumatology 37 2010 125 130
29. S.I. Nihtyanova, J.C. Parker, C.M. Black, C.C. Bunn, and C.P. Denton A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis Rheumatology (Oxford) 48 2009 1218 1221
30. A.A. Shah, and A. Rosen Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications Current Opinion in Rheumatology 23 2011 530 535
31. G. Riemekasten, A. Philippe, M. Näther, T. Slowinski, D.N. Müller, and H. Heidecke Involvement of functional autoantibodies against vascular receptors in systemic sclerosis Annals of the Rheumatic Diseases 70 2011 530 536
32. F. Ogawa, K. Shimizu, T. Hara, E. Muroi, K. Komura, and M. Takenaka Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxide reductase A, in systemic sclerosis: association with pulmonary fibrosis and vascular damage Archives of Dermatological Research 302 2010 27 35
33. S.S. Baroni, M. Santillo, F. Bevilacqua, M. Luchetti, T. Spadoni, and M. Mancini Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis The New England Journal of Medicine 354 2006 2667 2676
34. M. Manetti, E. Neumann, A. Müller, T. Schmeiser, P. Saar, and A.F. Milia Endothelial/lymphocyte activation leads to prominent CD4 + T cell infiltration in the gastric mucosa of patients with systemic sclerosis Arthritis and Rheumatism 58 2008 2866 2873
35. G.H. Stummvoll, M. Aringer, J. Grisar, C.W. Steiner, J.S. Smolen, and R. Knobler Increased transendothelial migration of scleroderma lymphocytes Annals of the Rheumatic Diseases 63 2004 569 574 (Pubitemid 38530202)
36. T.A. Medsger Jr., D.E. Ivanco, L. Kardava, P.A. Morel, M.R. Lucas, and P. Fuschiotti GATA-3 up-regulation in CD8 + T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production Arthritis and Rheumatism 63 2011 1738 1747
37. R.B. Christmann, E. Hayes, S. Pendergrass, C. Padilla, G. Farina, and A.J. Affandi Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension Arthritis and Rheumatism 63 2011 1718 1728
38. M.L. Eloranta, K. Franck-Larsson, T. Lövgren, S. Kalamajski, A. Rönnblom, and K. Rubin Type I interferon system activation and association with disease manifestations in systemic sclerosis Annals of the Rheumatic Diseases 69 2010 1396 1402
39. D. Fenoglio, F. Battaglia, A. Parodi, S. Stringara, S. Negrini, and N. Panico Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis Clinical Immunology 139 2011 249 257
40. R. Lafyatis, C. O'Hara, C.A. Feghali-Bostwick, and E. Matteson B cell infiltration in systemic sclerosis-associated interstitial lung disease Arthritis and Rheumatism 56 2007 3167 3168 (Pubitemid 47502765)
41. S. Sato, M. Fujimoto, M. Hasegawa, and K. Takehara Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells Arthritis and Rheumatism 50 2004 1918 1927 (Pubitemid 38725103)
42. M. Hasegawa, Y. Hamaguchi, K. Yanaba, J.D. Bouaziz, J. Uchida, and M. Fujimoto B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis American Journal of Pathology 169 2006 954 966 (Pubitemid 44411958)
43. T. Matsushita, M. Hasegawa, K. Yanaba, M. Kodera, K. Takehara, and S. Sato Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes Arthritis and Rheumatism 54 2006 192 201 (Pubitemid 43122202)
44. S. Bosello, M. De Santis, G. Lama, C. Span, C. Angelucci, and B. Tolusso B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial Arthritis Research and Therapy 12 2010 R54
45. Y. Shima, Y. Kuwahara, H. Murota, S. Kitaba, M. Kawai, and T. Hirano The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab Rheumatology (Oxford) 49 2010 2408 2412
46. N. Aden, A. Nuttall, X. Shiwen, P. de Winter, A. Leask, and C.M. Black Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis Journal of Investigative Dermatology 130 2010 2191 2200
47. B.C. Willis, R.M. du Bois, and Z. Borok Epithelial origin of myofibroblasts during fibrosis in the lung Proceedings of the American Thoracic Society 3 2006 377 382 (Pubitemid 43845416)
48. A.B. Roberts, A. Russo, A. Felici, and K.C. Flanders Smad3: a key player in pathogenetic mechanisms dependent on TGFβ Annals of the New York Academy of Sciences 995 2003 1 10 (Pubitemid 36706609)
49. Y. Chen, A. Leask, D.J. Abraham, L. Kennedy, X. Shi-Wen, and C.P. Denton Thrombospondin 1 is a key mediator of transforming growth factor β-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism Fibrogenesis Tissue Repair 4 2011 9
50. F. Fang, K. Ooka, S. Bhattacharyya, J. Wei, M. Wu, and P. Du The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses American Journal of Pathology 178 2011 2077 2090
51. J. Wei, A.K. Ghosh, J.L. Sargent, K. Komura, M. Wu, and Q.Q. Huang PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis PLoS One 2 2010 5 e13778
52. S. Bhattacharyya, M. Wu, F. Fang, W. Tourtellotte, C. Feghali-Bostwick, and J. Varga Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy Matrix Biology 30 2011 235 242
53. C. Skhirtladze, O. Distler, C. Dees, A. Akhmetshina, N. Busch, and P. Venalis Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis Arthritis and Rheumatism 58 2008 1475 1484 (Pubitemid 351705937)
54. A. Akhmetshina, P. Venalis, C. Dees, N. Busch, J. Zwerina, and G. Schett Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis Arthritis and Rheumatism 60 2009 219 224
55. B. Ma, Z. Zhu, R.J. Homer, C. Gerard, R. Strieter, and J.A. Elias The C10/CCL6 chemokine and CCR1 play critical roles in the pathogenesis of IL-13-induced inflammation and remodelling Journal of Immunology 172 2004 1872 1881 (Pubitemid 38116837)
56. N.A. Bhowmick, A. Chytil, D. Plieth, A.E. Gorska, N. Dumont, and S. Shappell TGFβ signalling in fibroblasts modulates the oncogenic potential of adjacent epithelia Science 303 2004 848 851 (Pubitemid 38174665)
57. A.J. Tyndall, B. Bannert, M. Vonk, P. Air, F. Cozzi, and P.E. Carreira Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database Annals of the Rheumatic Diseases 69 2010 1809 1815
58. F.M. Wigley, R.A. Wise, J.R. Seibold, D.A. McCloskey, G. Kujala, and T.A. Medsger Jr. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study Annals of Internal Medicine 120 1994 199 206
59. R. Stratton, X. Shiwen, G. Martini, A. Holmes, A. Leask, and T. Haberberger Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients Journal of Clinical Investigation 108 2001 241 250 (Pubitemid 32656248)
60. C.P. Denton, M. Humbert, L. Rubin, and C.M. Black Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions Annals of the Rheumatic Diseases 65 2006 1336 1340 (Pubitemid 44620443)
61. R.E. Girgis, A.E. Frost, N.S. Hill, E.M. Horn, D. Langleben, and V.V. McLaughlin Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease Annals of the Rheumatic Diseases 66 2007 1467 1472 (Pubitemid 350032654)
62. D.B. Badesch, N.S. Hill, G. Burgess, L.J. Rubin, R.J. Barst, and N. Gali Sildenafil for pulmonary arterial hypertension associated with connective tissue disease Journal of Rheumatology 34 2007 2417 2422 (Pubitemid 350230665)
63. R.J. Oudiz, R.J. Schilz, R.J. Barst, N. Galié, S. Rich, and L.J. Rubin Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease Chest 126 2004 420 427 (Pubitemid 39093426)
64. D.B. Badesch, M.D. McGoon, R.J. Barst, V.F. Tapson, L.J. Rubin, and F.M. Wigley Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol Journal of Rheumatology 36 2009 2244 2249
65. C.P. Denton, J.E. Pope, H.H. Peter, A. Gabrielli, A. Boonstra, and F.H. van den Hoogen Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases Annals of the Rheumatic Diseases 67 2008 1222 1228
66. J.H. Korn, M. Mayes, M. Matucci Cerinic, M. Rainisio, J. Pope, and E. Hachulla Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist Arthritis and Rheumatism 50 2004 3985 3993 (Pubitemid 39643947)
67. M. Matucci-Cerinic, C.P. Denton, D.E. Furst, M.D. Mayes, V.M. Hsu, and P. Carpentier Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomized, double-blind, placebo-controlled trial Annals of the Rheumatic Diseases 70 2011 32 38
68. C.S. Brueckner, M.O. Becker, T. Kroencke, D. Huscher, H.U. Scherer, and M. Worm Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study Annals of the Rheumatic Diseases 69 2010 1475 1478
69. D.P. Tashkin, R. Elashoff, P.J. Clements, J. Goldin, M.D. Roth, and D.E. Furst Cyclophosphamide versus placebo in scleroderma lung disease The New England Journal of Medicine 354 2006 2655 2666
70. R.K. Hoyles, R.W. Ellis, J. Wellsbury, B. Lees, P. Newlands, and N.S. Goh A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma Arthritis and Rheumatism 54 2006 3962 3970 (Pubitemid 44955900)
71. O. Kowal-Bielecka, R. Landewé, J. Avouac, S. Chwiesko, I. Miniati, and L. Czirjak EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) Annals of the Rheumatic Diseases 68 2009 620 628
72. D. McGonagle, A.L. Tan, J. Madden, A.C. Rawstron, A. Rehman, and P. Emery Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab Rheumatology (Oxford) 47 2008 552 553
73. D. Daoussis, S.N. Liossis, A.C. Tsamandas, C. Kalogeropoulou, A. Kazantzi, and C. Sirinian Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study Rheumatology (Oxford) 49 2010 271 280
74. J.J. Swigris, A.L. Olson, A. Fischer, D.A. Lynch, G.P. Cosgrove, and S.K. Frankel Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease Chest 130 2006 30 36 (Pubitemid 44116838)
75. A.C. Zamora, P.J. Wolters, H.R. Collard, M.K. Connolly, B.M. Elicker, and W.R. Webb Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease Respiratory Medicine 102 2008 150 155 (Pubitemid 350151821)
76. A.J. Gerbino, C.H. Goss, and J.A. Molitor Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease Chest 133 2008 455 460 (Pubitemid 351272405)
77. S.N. Liossis, A. Bounas, and A.P. Andonopoulos Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease Rheumatology (Oxford) 45 2006 1005 1008 (Pubitemid 44283057)
78. A. Olivieri, F. Locatelli, M. Zecca, A. Sanna, M. Cimminiello, and R. Raimondi Imatinib for refractory chronic graft-versus-host disease with fibrotic features Blood 114 2009 709 718
79. H.A. Ghofrani, W. Seeger, and F. Grimminger Imatinib for the treatment of pulmonary arterial hypertension The New England Journal of Medicine 353 2005 1412 1413 (Pubitemid 41362714)
80. J.H. Distler, B. Manger, B.M. Spriewald, G. Schett, and O. Distler Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease Arthritis and Rheumatism 58 2008 2538 2542
81. I. Sabnani, M.J. Zucker, E.D. Rosenstein, D.A. Baran, L.H. Arroyo, and P. Tsang A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide Rheumatology (Oxford) 48 2009 49 52
82. S.I. Nihtyanova, G.M. Brough, C.M. Black, and C.P. Denton Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis Rheumatology (Oxford) 46 2007 442 445 (Pubitemid 46344656)
83. R.F. Spiera, J.K. Gordon, J.N. Mersten, C.M. Magro, M. Mehta, and H.F. Wildman Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial Annals of the Rheumatic Diseases 70 2011 1003 1009
84. J. Pope, D. McBain, L. Petrlich, S. Watson, L. Vanderhoek, and F. de Leon Imatinib in active diffuse systemic sclerosis: results of a six-mongh, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center Arthritis and Rheumatism 63 2011 3546 3551
85. D. Khanna, R. Saggar, M.D. Mayes, F. Abtin, P.J. Clements, and P. Maranian A one-year, phase i?iia, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease Arthritis and Rheumatism 63 2011 3540 3546
86. C.E. Daniels, J.A. Lasky, A.H. Limper, K. Mieras, E. Gabor, and D.R. Schroeder Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results American Journal of Respiratory and Critical Care Medicine 181 2010 604 610
87. Z. Tamaki, Y. Asano, M. Hatano, A. Yao, T. Kawashima, and M. Tomita Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases Modern Rheumatology 2011 Jun 3 [Epub ahead of print]
88. J.H. Distler, S. Jordan, P. Airo, J.J. Alegre-Sancho, Y. Allanore, and A. Balbir Gurman Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique Clinical and Experimental Rheumatology 29 2011 S40 S45
89. M.C. Vonk, Z. Marjanovic, F.H. van den Hoogen, S. Zohar, A.V. Schattenberg, and W.E. Fibbe Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis Annals of the Rheumatic Diseases 67 2008 98 104
90. S. Guiducci, F. Porta, R. Saccardi, S. Guidi, L. Ibba-Manneschi, and M. Manetti Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report Annals of Internal Medicine 153 2010 650 654